Page last updated: 2024-12-08
echinoside a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
echinoside A: RN given refers to Na salt; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 156831 |
MeSH ID | M0128930 |
Synonyms (6)
Synonym |
---|
echinoside a |
(3beta,12alpha)-12,17,20-trihydroxy-3-((o-3-o-methyl-beta-d-glucopyranosyl-(1-3)-o-beta-d-glucopyranosyl-(1-4)-o-6-deoxy-beta-d-glucopyranosyl-(1-2)-4-o-sulfo-beta-d-xylopyranosyl)-oxy)lanost-9(11)-en-18-oic acid gamma-lactone, monosodium salt |
holothurin a2 |
75410-53-6 |
lanost-9(11)-en-18-oic acid, 12,17,20-trihydroxy-3-((o-3-o-methyl-beta-d-glucopyranosyl-(1-3)-o-beta-d-glucopyranosyl-(1-4)-o-6-deoxy-beta-d-glucopyranosyl-(1-2)-4-o-sulfo-beta-d-xylopyranosyl)oxy)-, gamma-lactone, monosodium salt, (3beta,12alpha)- |
sodium;[5-[5-[4-[3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-[[5,10-dihydroxy-2,6,13,17,17-pentamethyl-6-(4-methylpentyl)-8-oxo-7-oxapentacyclo[10.8.0.02,9.05,9. |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (15)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (13.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 11 (73.33) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 18.14
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.14) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (6.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (93.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |